• BioVaxys Technology Corp. (BIOV) and Ohio State University have made progress on creating a universal vaccine to treat a broad range of SARS viruses
  • BioVaxys is a clinical-stage biotechnology company developing vaccines
  • It just completed the preparation of the surrogate virus neutralization assays for COVID-19 variants
  • The company’s next step will be immunizing test animals with its BVX-1021 vaccine
  • It is expecting to see the data from this test trial sometime during August
  • BioVaxys Technology Corp. (BIOV) is unchanged trading at $0.11 per share as of 2:48 p.m. ET

BioVaxys (BIOV) and Ohio State University report progress on a universal vaccine to treat a range of SARS viruses.

BioVaxys is a Vancouver-based clinical stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

According to BioVaxys, it has completed preparation of the surrogate virus neutralization assays for the COVID-19 variants, including those that are transmitted between pangolins and bats. The company’s next step will be immunizing test animals with BVX-1021, its “booster” vaccine which will be given alongside established COVID-19 vaccines.

BVX-1021 is undergoing continuous research collaboration between Ohio State and BioVaxys. The partnership started earlier this year. The tests will use a guinea pig model.

The companies goals of the study are the development of virus-neutralizing antibodies to live virus SARS viruses.

Recent yields of the company’s recombinant SARS-1 protein obtained from an external supplier to use for BVX-1021 production were determined to contain the presence of a natural protein aggregate byproduct in addition to the SARS-1 protein. 

“Our team felt it prudent for scientific reproducibility to re-synthesize a new yield of recombinant SARS-1 protein specifically screening out the extraneous protein aggregate,” Kenneth Kovan, President and COO of BioVaxys, said.

“The COVID-19 lockdown situation in Shanghai further impacted the lead time for production of the SARS-1 protein by our Shanghai-based supplier.”

 BioVaxys is expecting to see the data from this test trial sometime during August.

BioVaxys Technology Corp. (BIOV) is unchanged trading at $0.11 per share as of 2:48 p.m. ET.

More From The Market Online
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.

Cannabis stock jumps on news its products are coming to Canada

Ovation Science Inc. (CSE:OVAT) signs an exclusive licensing agreement for its products in Canada with Ripco Processing Inc.